Health ❯ Healthcare

Cancer Research

Clinical Trials Immunotherapy Biomarkers Tumor Microenvironment Tumor Biology Survival Rates Clinical Studies Innovative Therapies Epidemiology Therapeutics

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

If approved, the move would let doctors treat HRR-driven prostate cancer earlier to help delay progression in the hormone-sensitive stage.

WashU Team Uses In‑Body Click Chemistry to Assemble Dual‑Target Cancer Drugs

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

Study Finds Large Gaps in Cancer Screening for Sexual and Gender Minority Adults

Mumbai Deploys 24 Trained Cancer Patient Navigators Across City Wards

Engineered CAR T Cells Targeting MUC16 Control Bladder Tumors in Mice

Andy Cohen Leads Tribute After WWHL Producer Kyra Samson Dies at 28

NICE Approves Pembrolizumab with Chemoradiotherapy for Locally Advanced Cervical Cancer

Daraxonrasib Doubles Survival in Phase 3 Trial for Advanced Pancreatic Cancer

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

Penn Study Finds About 30% Lower Breast Cancer Rates Associated With GLP‑1 Use

Hetairos AI Classifies 102 Brain Tumor Subtypes from Routine Slides in Minutes

NHS to Roll Out Five-Session Precision Radiotherapy for Early Prostate Cancer

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

Princess of Wales Makes Emotional Solo Visit to The Christie

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Grail’s Galleri Misses NHS Trial Target and Seeks More Follow‑Up Data

Penn Study Finds About 30% Lower Breast Cancer Incidence Among Women Prescribed GLP‑1 Drugs